The new study shows that inhaled nitric oxide actually saves a lot of money when compared to the older and more invasive ECMO procedures:For every 100 newborns with HRF, treatment resulted with inhaled nitric oxide in a cost savings of more than $ 440 These savings occurred in neonates who do not need to be transferred to another hospital for ECMO treatment much of the savings resulting from the avoidance of ECMO, a costly operation treating newborns with inhaled nitric oxide at local hospitals is cost-effective , if the treatment prevents the need for ECMO, but also prevents the cost of transmitting the babies The ECMO center. – using data from two randomized controlled trials and other real-life experiences with ECMO and inhaled nitric oxide, developed by researchers at the University of Pittsburgh lab CrisMa a cost-benefit model In December 1999covery.
HRF develops in newborns whose lungs can not deliver enough oxygen to their bodies bluish bluish and endangering their lives.The condition often appears on the first day after birth, and affects about 30,000 full-term and short-term infants every year. There is no prenatal test or other way to predict which babies develop HRF, so there is no known way to prevent the state – .We believe that Initiate Exploratory Interferon Sparing Clinical Trial Of PSI-7977 in chronic hepatitis C.
Pharmasset announced that it begun dose at of an exploratory study of the PSI-7977 an nucleotide analogue is polymerase inhibitor, for the treatment chronic hepatitis C . The study is assessed PSI-7977 400mg QDs used in combination with ribavirin , 8 and with pegylated interferon pegylated interferon alfa-2a in treatment-naive patients infects to Genotype 2 or 3. Source: Pharmasset.